US Biotechnology Small/Mid Cap: Biotech Bull / Bear Debate – Summit Therapeutics Inc (SMMT)
UBS presents a bull/bear debate on Summit Therapeutics (SMMT), focused on ivonescimab, a first-in-class PD-1xVEGF bispecific that was the first drug in…
Companies
Summit Therapeutics
Summit Therapeutics research hub covering institutional report mentions, AI summaries, related topics and market context.
1 reports